Crenezumab, an anti-amyloid β (Abeta) antibody which Genentech in-licensed from AC Immune SA, failed to reach the primary endpoint of two phase II studies in Alzheimer's disease, but the drug has demonstrated tantalizing signs of efficacy in patients at the milder end of the Alzheimer's spectrum.